Omadacycline

Omadacycline
Clinical data
Pronunciationoh mad" a sye' kleen
Trade namesNuzyra
Other namesPTK-0796,[1] BAY 73-6944
AHFS/Drugs.comMonograph
MedlinePlusa618066
License data
Routes of
administration		By mouth, intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC29H40N4O7
Molar mass556.660 g·mol−1
3D model (JSmol)
  • CC(C)(C)CNCc1cc(c2c(c1O)C(=O)C3=C([C@]4([C@@H](C[C@@H]3C2)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)N(C)C
  • InChI=1S/C29H40N4O7/c1-28(2,3)12-31-11-14-10-17(32(4)5)15-8-13-9-16-21(33(6)7)24(36)20(27(30)39)26(38)29(16,40)25(37)18(13)23(35)19(15)22(14)34/h10,13,16,21,31,34,36-37,40H,8-9,11-12H2,1-7H3,(H2,30,39)/t13-,16-,21-,29-/m0/s1
  • Key:JEECQCWWSTZDCK-IQZGDKDPSA-N

Omadacycline, sold under the brand name Nuzyra, is a broad spectrum antibiotic medication belonging to the aminomethylcycline subclass[3] of tetracycline antibiotics. In the United States, it was approved in October 2018, for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections.[2][4]

  1. ^ Boggs J. "Antibiotic Firm Paratek Joins IPO Queue; Aiming for $92M". bioworld.com. Clarivate Analytics. Archived from the original on 18 October 2017. Retrieved 17 October 2017.
  2. ^ a b "Nuzyra- omadacycline injection, powder, lyophilized, for solution; Nuzyra- omadacycline tablet, film coated". DailyMed. 3 June 2021. Retrieved 1 January 2024.
  3. ^ Honeyman L, Ismail M, Nelson ML, Bhatia B, Bowser TE, Chen J, et al. (November 2015). "Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline". Antimicrobial Agents and Chemotherapy. 59 (11): 7044–53. doi:10.1128/AAC.01536-15. PMC 4604364. PMID 26349824.
  4. ^ "Drug Approval Package: Nuzyra". U.S. Food and Drug Administration (FDA). 8 November 2018. Retrieved 1 January 2024.